OXFORD BIOMEDICA (UK) LIMITED
Get an alert when OXFORD BIOMEDICA (UK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-03-13 (in 10mo)
Last made up 2026-02-27
Watchouts
None on the register
Cash
£35M
-64.7% vs 2023
Net assets
-£201M
-13.8% vs 2023
Employees
569
-20.3% vs 2023
Profit before tax
-£24M
+51.9% vs 2023
Name history
Renamed 3 times since incorporation
- OXFORD BIOMEDICA (UK) LIMITED 1996-10-30 → present
- OXFORD BIOMEDICA LIMITED 1996-03-19 → 1996-10-30
- OXFORD GENETIC THERAPEUTICS LIMITED 1995-04-24 → 1996-03-19
- INSUREBLOOM LIMITED 1995-03-03 → 1995-04-24
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £64,928,000 | £129,677,000 | |
| Operating profit | -£52,977,000 | -£25,390,000 | |
| Profit before tax | -£49,981,000 | -£24,035,000 | |
| Net profit | -£51,524,000 | -£25,799,000 | |
| Cash | £99,872,000 | £35,247,000 | |
| Total assets less current liabilities | -£154,326,000 | -£184,967,000 | |
| Net assets | -£176,546,000 | -£200,876,000 | |
| Equity | -£176,547,000 | -£200,875,000 | |
| Average employees | 714 | 569 | |
| Wages | £44,887,000 | £35,565,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -81.6% | -19.6% | |
| Net margin | -79.4% | -19.9% | |
| Return on capital employed | 34.3% | 13.7% | |
| Gearing (liabilities / total assets) | 195.7% | 238.7% | |
| Current ratio | 9.64x | 6.15x | |
| Interest cover | -33.87x | -16.97x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company is reliant on the financial support of its Parent Company, Oxford Biomedica plc. The Parent Company has confirmed to the Directors of Oxford Biomedica (UK) Limited their intention to continue to provide financial support to the Company for a period of at least 12 months from the date of approval of these Financial Statements.”
Group structure
- OXFORD BIOMEDICA (UK) LIMITED · parent
- Invivusbio Limited 100%
Significant events
- “In June 2025, the intercompany receivable due to Oxford Biomedica (UK) Limited from OXB France of £6.1 million was repaid by Oxford Biomedica plc.”
- “In August 2025, the OXB Group entered into a new four-year term loan facility of up to $125 million with Oaktree Capital Management, L.P. ("Oaktree"), drawing $60 million (£45.3 million) on completion to refinance the existing $50 million (£37.8 million) facility.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WALTER, Natalie Louise | Secretary | 2019-07-24 | — | — |
| CRABTREE, Lucinda Claire, Dr. | Director | 2024-09-02 | Aug 1979 | British |
| MATHIAS, Frank, Dr | Director | 2023-03-27 | Sep 1962 | French |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| KINGSMAN, Susan Mary, Professor | Secretary | 1995-03-15 | 1996-12-13 |
| PAYNTER, Stuart | Secretary | 2017-10-01 | 2019-07-24 |
| WATTS, Timothy William | Secretary | 2012-02-10 | 2017-09-30 |
| WOOD, Andrew Brian | Secretary | 1996-12-13 | 2012-02-09 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 1995-03-03 | 1995-03-15 |
| BLAKE, Paul, Dr | Director | 2014-09-02 | 2016-08-31 |
| CLARK, June | Director | 1996-09-02 | 1997-05-08 |
| DAWSON, John Andrew | Director | 2009-04-20 | 2022-05-27 |
| DOLIVEUX, Frederic Roch | Director | 2022-05-18 | 2023-03-27 |
| DURRANDS, Paul Kenneth, Dr | Director | 2000-06-22 | 2002-04-30 |
| GOODMAN, Alan Gilbert | Director | 1996-05-20 | 1997-02-27 |
| KINGSMAN, Alan John, Professor | Director | 1995-03-15 | 2011-05-05 |
| KINGSMAN, Susan Mary, Professor | Director | 1995-03-15 | 2008-07-01 |
| MACKENZIE, Neill Moray, Dr | Director | 1996-09-01 | 2002-11-30 |
| NOLAN, Peter John | Director | 2002-05-01 | 2018-07-02 |
| PAYNTER, Stuart | Director | 2017-08-29 | 2024-09-02 |
| RICHARDS, Brian Mansel, Sir | Director | 1996-05-20 | 1998-06-26 |
| TURNER, Roger John Langdon | Director | 1996-08-09 | 1996-12-31 |
| WATTS, Timothy William | Director | 2012-02-10 | 2017-09-30 |
| WOOD, Andrew Brian | Director | 1996-12-13 | 2012-02-09 |
| INSTANT COMPANIES LIMITED | Corporate Nominee Director | 1995-03-03 | 1995-03-15 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Oxford Biomedica Plc | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 159 total filings
Material constitutional events — rename, articles re-file, resolution
- 2022-03-28 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-07 | AA | accounts | Accounts with accounts type full | |
| 2025-08-05 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-08-04 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-08-04 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-03-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-21 | AA | accounts | Accounts with accounts type full | |
| 2024-09-03 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-03 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-10 | MR05 | mortgage | Mortgage charge part both with charge number | |
| 2023-07-24 | AA | accounts | Accounts with accounts type full | |
| 2023-03-29 | TM01 | officers | Termination director company with name termination date | |
| 2023-03-29 | AP01 | officers | Appoint person director company with name date | |
| 2023-03-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-05 | MR05 | mortgage | Mortgage charge part both with charge number | |
| 2022-08-17 | AA | accounts | Accounts with accounts type full | |
| 2022-05-27 | TM01 | officers | Termination director company with name termination date | |
| 2022-05-26 | AP01 | officers | Appoint person director company with name date | |
| 2022-03-28 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+99.7%
£64,928,000 £129,677,000
-
Cash
-64.7%
£99,872,000 £35,247,000
-
Net assets
-13.8%
-£176,546,000 -£200,876,000
-
Employees
-20.3%
714 569
-
Operating profit
+52.1%
-£52,977,000 -£25,390,000
-
Profit before tax
+51.9%
-£49,981,000 -£24,035,000
-
Wages
-20.8%
£44,887,000 £35,565,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers